RxDoctor Payments Data

Marc Cohen, MD

Neurology · Anderson, INNPI 1942461165

Payments from drug & device makers

$13,406in general payments, 2019–2025

Across 700 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • EMD Serono, Inc.$1K
  • Novartis$931
  • Sanofi$814
  • Biogen$797
  • UCB, Inc.$788
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$3002%
  • Speaking & faculty fees$2001%
  • Food & beverage$12,90696%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)148$2,021
EMD Serono, Inc.51$1,233
Novartis78$931
Sanofi20$814
Biogen27$797
UCB, Inc.42$788
MDD US Operations, LLC16$787
Amgen(2 entities)24$496
Livanova USA, Inc.9$423
AstraZeneca12$407
Catalyst Pharmaceuticals, Inc.11$358
Eisai Inc.18$319
Lilly USA, LLC16$279
Neurelis, Inc.9$263
Neurocrine Biosciences, Inc.13$258
SK Life Science, Inc.11$228
Acadia Pharmaceuticals Inc15$220
Jazz Pharmaceuticals Inc.10$216
Teva Pharmaceuticals USA, Inc.12$176
Lundbeck LLC10$173
Pfizer11$171
TG Therapeutics, Inc.8$158
Amneal Pharmaceuticals LLC6$155
Supernus Pharmaceuticals, Inc.27$136
Bristol Myers Squibb7$120
Argenx US, Inc.6$101
Genentech USA, Inc.6$100
Avanir Pharmaceuticals, Inc.6$96
Tanabe Pharma America, Inc.6$92
Harmony Biosciences LLC3$72
Otsuka America Pharmaceutical, Inc.4$68
Vanda Pharmaceuticals Inc.3$63
Scilex Pharmaceuticals Inc.4$61
Banner Life Sciences, LLC3$58
Adamas Pharmaceuticals, Inc.4$58
Biohaven Pharmaceuticals, Inc.4$56
CSL Behring3$53
Biohaven Pharmaceutical Holding Company Ltd.3$44
Promius Pharma LLC3$43
Sumitomo Pharma America, Inc.4$40
Takeda Pharmaceuticals U.S.A., Inc.2$38
Avadel CNS Pharmaceuticals, LLC2$36
Globus Medical1$34
Axsome Therapeutics, Inc.2$31
Zyla Life Sciences, Inc.2$30
Grifols USA, LLC2$30
Kyowa Kirin, Inc.2$25
Abbott1$24
Aucta Pharmaceuticals, Inc.1$23
Vertical Pharmaceuticals, LLC1$22
Merz Pharmaceuticals, LLC1$20
Sunovion Pharmaceuticals Inc.1$19
Mallinckrodt Hospital Products Inc.1$18
Assertio Therapeutics, Inc.1$18
Azurity Pharmaceuticals, Inc.1$17
Johnson & Johnson1$16
Ipsen Biopharmaceuticals, Inc1$16
OWP Pharmaceuticals, Inc.1$15
Greenwich Biosciences, Inc.1$14
Acorda Therapeutics, Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,406 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$493,276
Medicare patients
459
Services billed
9,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate33$161,652
Kesimpta PenOfatumumab15$130,336
IngrezzaValbenazine Tosylate15$122,798
Aimovig AutoinjectorErenumab-Aooe67$55,266
EpidiolexCannabidiol (Cbd)12$33,017
Memantine Hcl499$21,873
Nurtec OdtRimegepant Sulfate19$19,528
RexultiBrexpiprazole24$17,322
UbrelvyUbrogepant13$14,673
FingolimodFingolimod Hcl12$11,341
Gabapentin298$10,953
Pregabalin83$10,755
Emgality PenGalcanezumab-Gnlm15$10,359
Lacosamide34$10,106
Levetiracetam219$9,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$220$161,65233 claims
Neurocrine Biosciences, Inc.Ingrezza$258$122,79815 claims
PfizerNurtec Odt$171$19,52819 claims
Otsuka America Pharmaceutical, Inc.Rexulti$68$17,32224 claims
AbbVieUbrelvy$2,021$14,67313 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$155$2,48711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 308 neurology providers in Indiana.

Other neurology in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →